A new article in JOJ Ophthalmology confirms Tixel i® provides sustained, strong clinical outcomes for patients with Evaporative Dry Eye Disease (DED) caused by Meibomian Gland Dysfunction (MGD). This FDA-cleared, non-invasive device uses patented Thermo-Mechanical Action® (TMA®) to deliver durable improvements in key indicators, including patient satisfaction and clinical results.

A recent study published in JOJ Ophthalmology highlights the strong clinical performance of Tixel i® in treating Evaporative Dry Eye Disease (DED) caused by Meibomian Gland Dysfunction (MGD). Key outcomes include a significant improvement in Tear Break-Up Time (TBUT), which increased from 4.0 ± 1.5 seconds to 9.2 ± 4.0 seconds—reaching normal physiological levels. The Meibomian Gland Score (MGS) rose by over 17 points, matching or surpassing results from leading thermal pulsation systems. Patients also experienced a drop of over 21 points in their Ocular Surface Disease Index (OSDI) scores, indicating a notable reduction in symptoms and enhanced quality of life. Importantly, no device-related adverse effects were reported, underscoring the safety of the treatment.

One 76-year-old patient with severe dry eye, unable to tolerate traditional treatments like IPL, found significant relief with Tixel i. Dr. Lauren Bailey of West Plano Dry Eye and Aesthetics noted, "It's quick, easy, and finally gave us a way forward after hitting so many walls. Tixel i is perfect for our low vision patients."

Dr. Bailey also treated a 53-year-old patient with a two-year history of severe dry eye that required eye drops four to six times daily. Following a treatment plan that included three sessions of Tixel i, the patient reported noticeable improvement in discomfort and a substantial reduction in the impact of dry eye on daily activities. By the four-week follow-up, her clinical severity had improved from severe to moderate, drop usage had decreased, and objective metrics showed dramatic improvement: TBUT increased from 0 to 8 seconds and MGSS improved from 2 to 40 (OD) and 39 (OS), leading to reduced eye drop usage and improved daily activities.